Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Rohde

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Science (New York, N.Y.)|March 31, 2018
A bound reaction intermediate sheds light on the mechanism of nitrogenaseDaniel Sippel, Michael Rohde, Julia Netzer, et al.
ACS Nano|November 14, 2025
Giant Anomalous Ettingshausen Effect and Hybrid Longitudinal-Transverse Thermoelectric Cooling in a Nanoscale Magnetic Weyl SemimetalMohammadali Razeghi, Jean Spiece, Valentin Fonck, et al.
Wiener Medizinische Wochenschrift (1946)|April 19, 2008
Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapyEdgar Petru, Johannes Andel, Lukas Angleitner-Boubenizek, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Science (New York, N.Y.)|March 31, 2018
A bound reaction intermediate sheds light on the mechanism of nitrogenaseDaniel Sippel, Michael Rohde, Julia Netzer, et al.
ACS Nano|November 14, 2025
Giant Anomalous Ettingshausen Effect and Hybrid Longitudinal-Transverse Thermoelectric Cooling in a Nanoscale Magnetic Weyl SemimetalMohammadali Razeghi, Jean Spiece, Valentin Fonck, et al.
Wiener Medizinische Wochenschrift (1946)|April 19, 2008
Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapyEdgar Petru, Johannes Andel, Lukas Angleitner-Boubenizek, et al.
Pageof 2